The Global Site-Specific Drug Delivery Market Report is equipped with market data from 2014 to 2024. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2019 to 2024. The detailed sales channel is also covered in the study.
The selective delivery of chemotherapeutic agents to their site of action should increase therapeutic effectiveness and limit side effects. Most drug therapies currently available, however, exhibit little, if any specificity. Many times, a drug has limited or no access to its intended site of action or is prematurely metabolized or excreted. In other instances, the drug travels rather freely throughout the body and not only acts on the desired target tissues but also causes undesirable effects on nontarget tissues. This lack of target specificity is attributable, for the most part, to the formidable barriers that the body presents to the successful delivery of a drug from its site of administration to its site of action: a drug normally encounters or must by pass various molecules, enzymes, cells, membranes, and organs before reaching its designated target.
Scope of the Report:
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Site-Specific Drug Delivery in US$ by following Product Segments.: Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel and other.
Company profiles are primarily based on public domain information including company
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
The global Site-Specific Drug Delivery market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Site-Specific Drug Delivery.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Site-Specific Drug Delivery market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Site-Specific Drug Delivery market by product type and applications/end industries.
Market Segment by Companies, this report covers
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Other
Market Segment by Applications, can be divided into
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Other